about
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activityA genome-wide association study in progressive multiple sclerosisA strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.Next Generation Sequencing of Pooled Samples: Guideline for Variants' Filtering.Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis.Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.COL6A5 variants in familial neuropathic chronic itch.Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.The burden of multiple sclerosis variants in continental Italians and Sardinians.Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis.Genetic burden of common variants in progressive and bout-onset multiple sclerosis.NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Laser capture microdissection for transcriptomic profiles in human skin biopsies.Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern EuropeansMicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkersInverse correlation of genetic risk score with age at onset in bout-onset and progressive-onset multiple sclerosisMGAT5 and disease severity in progressive multiple sclerosisNo C9orf72 repeat expansion in patients with primary progressive multiple sclerosis
P50
Q28261215-A3363C7F-A07B-45B3-91AB-0C6BC85AA8A2Q28943404-068EBF68-F8F5-4896-8DE6-962ECD987A1AQ34903557-72CC2759-DEE2-41A6-BE09-AE7D48723CE8Q35533986-8DD56441-BEF5-4A62-A519-09F6B6F2A115Q37285360-0D79FFCC-CDAD-4488-8C57-EC59B4E34596Q37322100-B5B1E318-EB47-498D-B2EB-1B71F541046EQ37690125-A61F1EC5-4280-4E35-8CA1-CA73F551DBB7Q37716786-907DE71A-1CE3-4E15-A91D-F68B3DC39234Q39161394-0F6A39A7-1532-4D5C-95AF-6BB69905EF82Q39900185-F918509A-73C2-4571-918A-8A047DB42C7CQ41260237-1D271687-5196-46D6-9996-B783920213B6Q41589802-45048C32-15C6-44E6-9881-A2ED168DDC3BQ45381521-710FDDB6-5657-47AC-83AE-BB8D9AA09ADDQ50104366-4A147BDB-E746-47BD-9620-51D77082ED0FQ52727172-0F5C2066-DBFF-402F-9109-8DB1FD21290AQ52897470-53A70087-3971-4261-8B2D-377D23A52471Q55413271-0D7EC20C-3842-41D4-9117-2F92C56F92BEQ59543670-74F188B8-EF7B-4193-80A9-503B2C6FFEC4Q59543676-E0BFE08A-6ECB-443B-972C-E55C97E4C6C1Q59683405-AAB6EF02-67CE-4A32-A998-AD14777DD3D3Q64042141-E19570E0-DE65-48BA-A6B3-BD44BC80BEE6Q64863610-21AC1494-FB2F-49C1-998B-CD4F448D4020
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Melissa Sorosina
@ast
Melissa Sorosina
@en
Melissa Sorosina
@es
Melissa Sorosina
@nl
type
label
Melissa Sorosina
@ast
Melissa Sorosina
@en
Melissa Sorosina
@es
Melissa Sorosina
@nl
prefLabel
Melissa Sorosina
@ast
Melissa Sorosina
@en
Melissa Sorosina
@es
Melissa Sorosina
@nl
P106
P1153
36638398200
P31
P496
0000-0003-4376-2550